Little-Known Company Harnessing the Power of AI-Breakthroughs Continues with Acquisitions in the $315 Billion Diagnostics Market… ^(1)(2)(24)

See why now could be the best time to start your research on Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon’s Laboratory Services MSO Announces Expansion into Arizona

Avalon GloboCare Corp. (Nasdaq: ALBT)

7 Reasons Why Avalon GloboCare Corp. (Nasdaq: ALBT) Could See Significant Upside Potential Ahead of 2024...

Strategic Acquisitions:

In a strategic move aimed at bolstering its presence in the healthcare industry and tapping into the lucrative $315 billion diagnostics market, Avalon GloboCare Corp. (Nasdaq: ALBT) has continued its acquisition spree, building upon its previous acquisition by making significant new additions through its subsidiary, Laboratory Services MSO, LLC. These acquisitions include Merlin Medical Supply, a reputable HME and DME company in Ventura County, California, as well as Leading Edge Innovations, LLC, the owner of the patented FDA-registered GeeWhiz External Condom Catheter. ^(6)(2)(24)

Intellectual Property:

In a significant stride towards pioneering medical innovation, Avalon GloboCare Corp. (Nasdaq: ALBT) has achieved a remarkable milestone. The United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled "QTY Fc Fusion Water Soluble Receptor Proteins." This patent represents a groundbreaking achievement in the realm of molecular biology and has the potential to reshape the landscape of therapeutic targeting. ⁽²⁵⁾

Avalon GloboCare Corp. (Nasdaq: ALBT)

Promising Growth Prospects in the Global Clinical Laboratory Service Market ⁽²⁾

The global clinical laboratory service market is poised for significant expansion, with an estimated value of $202 billion and projected growth surpassing $315 billion by 2030. This market is primarily driven by the increasing demand for early diagnostic tests and the rising prevalence of chronic diseases. The biotechnology and healthcare industries, particularly in developed regions like the U.S. and Canada, are experiencing rapid growth, further fueling the demand for clinical laboratory services. Government and private investments aimed at developing and expanding these industries are key drivers of market growth. ⁽²⁾

The rising prevalence of chronic diseases and increased investments in research laboratories have a significant impact on the demand for clinical laboratory services. Additionally, the need for efficient data storage and management, driven by the proliferation of research centers worldwide, contributes to market growth. The adoption of automated technologies to enhance productivity and reduce costs also augments the market’s expansion. Key players in the industry continually introduce new services to meet patient needs, further propelling market growth.

The clinical chemistry segment, which accounted for a significant revenue share, is projected to maintain its dominance throughout the forecast period. This segment benefits from the introduction of new technologies, a wide range of clinical chemistry tests, and the emergence of point-of-care testing methods. Moreover, investments in research activities by healthcare industry players drive the growth of laboratories globally, making the clinical chemistry segment the fastest-growing segment. ⁽²⁾

The human and tumor genetics tests segment is expected to register the highest growth rate, indicating the increasing importance of genetic testing in diagnosis and treatment.

Among service providers, hospital-based laboratories currently hold the largest revenue share. Factors such as the growing prevalence of cancer, research activities aimed at innovative services, and the rising demand for clinical chemistry services in hospitals contribute to the growth of this segment.

The toxicology testing services segment is anticipated to exhibit the fastest growth rate. Advancements in clinical diagnostic methods and increasing awareness about disease diagnosis and treatment contribute to the growth of this segment.

The global clinical laboratory service market offers promising growth prospects, driven by the increasing demand for early diagnostic tests and the rising prevalence of chronic diseases. Investments in research laboratories, automation technologies, and the introduction of new services by key players further contribute to market expansion. ⁽²⁾

As the market evolves, opportunities for growth and innovation abound. One little-known company to keep an eye on in this sector is Avalon GloboCare Corp. (Nasdaq: ALBT). This company could be extremely well-positioned to capitalize on these opportunities and make significant contributions to the advancement of the industry. ⁽⁸⁾

Avalon GloboCare Corp. (Nasdaq: ALBT)

Could Avalon GloboCare Corp. (Nasdaq: ALBT) Have as Much as 664% Potential Upside After Recently Bouncing Off Its 52-Week Low? ⁽³⁾

Look at the Avalon GloboCare Corp. (Nasdaq: ALBT) daily chart above and do a little technical analysis using StockCharts.com and Barchart.com. ^(10)(3)

As you can see, on 10/16/2023 the daily average price for (ALBT) was $.78.⁽³²⁾

Moving Averages:

50-Day: $.99
100-Day: $1.30
200-Day: $1.98

Then take a quick look Barchart.com and you’ll see the following: ⁽³⁾
2023 High: $5.20+
52-Week Low: $.68

Avalon GloboCare Corp. (Nasdaq: ALBT) is demonstrating the potential for significant upside with a 52-week low of $.68 and a 2023 high of $5.20. This could suggest a potential upside of over 664% after (ALBT) bounced off its 52-week low on 10/3/2023.⁽³⁾ Not that any returns to previous highs are certain for (ALBT) shares, but the potential for 664% upside suggests a strong reason to begin your research on this company.

Now, what if Avalon GloboCare Corp. (Nasdaq: ALBT) enters an oversold scenario?

According to Investopedia.com, two of the most common charting indicators of overbought or oversold conditions are the relative strength index (RSI) and stochastics. Developed by J. Welles Wilder Jr. and introduced in the 1978 book New Concepts in Technical Trading Systems, RSI is a measurement of stock price change momentum. ⁽²¹⁾

RSI is a range-bound oscillator, meaning that its value fluctuates between 0 and 100 depending on the underlying security performance, and is calculated based on prior periods’ average gains versus losses.

When the RSI indicator approaches 100, it suggests that the average gains increasingly exceed the average losses over the established time frame.

The higher the RSI, the stronger and more protracted the bullish trend. A long and aggressive downtrend, on the other hand, results in an RSI that progressively moves toward zero.

RSI levels of 80 or above are considered overbought, as this indicates an especially long run of successively higher prices. An RSI level of 30 or below is considered oversold. ⁽²¹⁾

As of 10/16/2023, StockCharts.com is reporting that Avalon GloboCare Corp. (Nasdaq: ALBT) has a 14-Day RSI of 35.90. ⁽¹⁰⁾ This suggests that shares of (ALBT) are around oversold territory and yet another reason to begin your research on this company.

Moreover, as of 10/16/2023, Avalon GloboCare Corp. (Nasdaq: ALBT) has a market cap of less than$8.7 million and fewer than 4.7 millionshares available in its public float according to MarketWatch.com. ⁽⁵⁾

Low float stocks have the potential to present significant swings due to volatility,(4) which could make (ALBT) an attractive watch target daily.

Additionally, Avalon GloboCare Corp. (Nasdaq: ALBT) insiders are holding onto many shares. According to the Avalon GloboCare Corp. (Nasdaq: ALBT) corporate presentation updated for June 2023, insiders own over 56% of shares. ⁽¹¹⁾

Strong insider ownership can be an indication of a company’s health and long-term potential. When insiders own a significant percentage of a company’s shares, they have a vested interest in the company’s success, which can align their interests with those of other shareholders.

High insider ownership typically signals that insiders believe in the company’s future prospects and have confidence in its management team.

This level of insider ownership could be a sign that the management team has a significant stake in the company’s success. When insiders own a large percentage of a company’s shares, it can also indicate that they are committed to the company for the long term, as they have a significant financial stake in its future performance.

The market often views high insider ownership as a positive signal, as it indicates that insiders are financially interested in the company’s success.

This can also provide shareholders with greater transparency into the company’s operations and decision-making processes, as insiders are more likely to share information with shareholders who have a vested interest in the company’s success.

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Makes Strategic Move in $315 Billion Diagnostics Market with Acquisition… ⁽¹⁾⁽²⁾

Earlier this year, Avalon GloboCare Corp. (NASDAQ: ALBT) announced its acquisition of a 40% interest in Laboratory Services MSO, LLC (LSM), a premier clinical diagnostics and reference laboratory. The transaction marks the launch of Avalon’s new rollup strategy targeting toxicology and pharmacogenetic laboratories. ⁽⁶⁾

Headquartered in Costa Mesa, California, LSM provides a wide range of diagnostic tests, including drug testing, toxicology, pharmacogenetics, and various test services, from general blood work to anatomic pathology. The laboratory also has a sophisticated and state-of-the-art facility for clinical diagnostics and reference laboratory.

The total consideration for the transaction was $21 million, with $9 million paid in cash, $11 million in shares of the Company’s Series B preferred stock, and $1 million in cash payable on February 9, 2024. The seller is also eligible to receive certain earnout payments upon achieving specific operating results, which could amount to $10,000,000. ⁽⁶⁾

The parties entered into an operating agreement in connection with the transaction, which includes a pro-rata percentage of LSM’s net income. Additionally, Avalon has an exclusive option to purchase an additional 20% of LSM for $6 million in cash and $4 million in additional shares of the Company’s Series B preferred stock.

David Jin, M.D., Ph.D President and Chief Executive Officer of Avalon, stated that this transaction is expected to be accretive to earnings and will add strong clinical and rollup synergies to the existing Avalon portfolio and future growth plan. Dr. Jin also expressed excitement about the potential to acquire a controlling interest in LSM within the next nine months.

Avalon aims to leverage LSM’s experience and infrastructure to achieve significant synergies with respect to revenue growth and market shares by targeting laboratories with exceptional performance, positive revenue track records, and niche-market advantage.

David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "We are excited to close this initial investment as a first step, and anticipate acquiring a controlling interest within the next nine months. Not only is this transaction expected to be accretive to our earnings, but we believe it also adds strong clinical and rollup synergies to the existing Avalon portfolio and future growth plan. By combining LSM’s established infrastructure with Avalon’s cutting-edge diagnostic and cellular immunotherapy platforms, it provides us with an established roadmap and framework in the context of integrating our CellTech/therapeutic programs with precision medicine.”

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Expands its Reach with Strategic Acquisition of DE Laboratory… ⁽²²⁾

In a significant move that underscores its commitment to expansion and innovation, Avalon GloboCare Corp. (Nasdaq: ALBT) announced its acquisition of DE Laboratory LLC, a reputable laboratory located in Houston, Texas. This strategic acquisition, executed by Avalon’s Laboratory Services MSO, LLC, presents a multitude of growth opportunities and solidifies Avalon’s presence within the dynamic landscape of laboratory testing and services. ⁽²²⁾

DE Labs has made its mark as a CLIA-certified and COLA-accredited laboratory, providing a comprehensive array of high-quality testing services. With a specialization in various crucial fields, including drug testing, genetic testing, urinary testing, and CV-19 PCR testing, DE Labs has emerged as a reliable destination for accurate diagnostics and analyses. Handling an impressive volume of 1,500 lab tests each month, the laboratory’s reputation for precision and efficiency has garnered the trust of both healthcare professionals and patients alike.

Avalon’s acquisition of DE Labs is not just a strategic decision, it’s a calculated move aimed at harnessing the vast potential for growth within the laboratory testing sector. The laboratory is now being operated as a wholly-owned subsidiary of LSM, with Avalon owning a substantial 40% interest in LSM. This ownership structure positions Avalon to leverage DE Labs’ expertise while contributing its own resources and insights to foster a symbiotic relationship.

One of the most compelling aspects of this acquisition is the planned expansion of DE Labs’ reach into the surrounding counties. With Avalon’s support, LSM is directing growth capital towards geographical expansion, allowing the laboratory to broaden its footprint and reach more individuals in need of its crucial testing services. This move aligns with Avalon’s overarching strategy of tapping into unique roll-up opportunities within the laboratory testing and services market, which is characterized by its fragmented nature.

David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, highlighted the strategic significance of this acquisition. He emphasized, “Our strategy is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services.” ⁽²²⁾

The aim is to identify laboratories with outstanding performance, proven revenue track records, and specialized advantages within niche markets. Through the integration of LSM’s operational experience and infrastructure, Avalon anticipates substantial synergies that will drive revenue growth and expand market share, solidifying its position as a key player in the laboratory services sector.

As the healthcare landscape continues to evolve, the role of laboratory testing in enabling accurate diagnostics, personalized treatment plans, and preventive care cannot be understated. The acquisition of DE Labs not only reflects Avalon GloboCare Corp. (Nasdaq: ALBT)’s commitment to innovation and expansion but also its dedication to contributing to advancements in healthcare delivery and patient outcomes.

Avalon GloboCare Corp. (Nasdaq: ALBT)’s acquisition of DE Laboratory LLC represents a pivotal move within the laboratory testing and services sector. This strategic decision capitalizes on the laboratory’s impressive track record, offering a wide spectrum of testing services, and positions Avalon for substantial growth. With an eye towards geographical expansion and synergistic collaboration, Avalon is poised to make a lasting impact on the healthcare industry, driving innovation and excellence in diagnostics and testing services. ⁽²²⁾

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Expands its Healthcare Footprint with Strategic Acquisitions… ⁽²⁴⁾

In a strategic move aimed at bolstering its presence in the healthcare industry, Avalon GloboCare Corp. (Nasdaq: ALBT) has made significant acquisitions through its subsidiary, Laboratory Services MSO, LLC (LSM). These acquisitions include Merlin Medical Supply (MMS), a prominent Home Medical Equipment (HME) and Durable Medical Equipment (DME) company in Ventura County, California, as well as Leading Edge Innovations, LLC, the owner of the patented FDA-registered GeeWhiz External Condom Catheter. ⁽²⁴⁾

In a strategic move aimed at bolstering its presence in the healthcare industry and tapping into the lucrative $315 billion diagnostics market, Avalon GloboCare Corp. (Nasdaq: ALBT) has continued its acquisition spree, building upon its previous acquisition by making significant new additions through its subsidiary, Laboratory Services MSO, LLC (“LSM”). These acquisitions include Merlin Medical Supply (“MMS”), a reputable HME and DME company in Ventura County, California, as well as Leading Edge Innovations, LLC, the owner of the patented FDA-registered GeeWhiz External Condom Catheter.

MMS: A Thriving Medical Supply Company ⁽²⁴⁾

Merlin Medical Supply, with over two decades of service to the Ventura community, has established itself as a reputable provider of acute and non-acute medical supplies. The company’s comprehensive range of services includes support for home healthcare needs. Crucially, MMS boasts contracts with major healthcare payers, including Medicaid, Medicare, Medi-Cal, Optum-Rx, CCS, Tri-Care, Blue Cross/Blue Shield, Humana, Aetna, United Health, and Gold Coast.⁽²⁴⁾

Dr. David Jin, President and Chief Executive Officer of Avalon, expressed his enthusiasm for the acquisition, stating,""MMS has been servicing the community in Ventura for over 20 years and is an in-network provider for major insurance companies, including Medicare and Medicaid. The medical supply market is expected to grow rapidly with the rising geriatric population, and MMS is well positioned to capitalize on this market opportunity given its established relationships with payers and clients." ⁽²⁴⁾

The acquisition of MMS aligns with Avalon GloboCare Corp. (Nasdaq: ALBT)’s strategic vision of expanding its healthcare services and creating a nationwide presence. By merging MMS into LSM, Avalon aims to support the expansion of this well-established player in the healthcare supply market.

GeeWhiz: A Game-Changing Male Catheter Device ⁽²⁴⁾

In addition to MMS, LSM has also acquired Leading Edge Innovations, LLC, which owns the GeeWhiz External Condom Catheter. This innovative device is patented, FDA-registered, and already available in the market. The GeeWhiz External Condom Catheter is designed to address male urinary incontinence and bladder control issues, offering a discreet and effective solution.

Dr. Jin emphasized the significance of this acquisition, saying, "LSM also acquired a proprietary, FDA-registered, external male catheter device - GeeWhiz. The GeeWhiz External Condom Catheter is approved for reimbursement by Medicare and a number of high-profile private insurance providers. The GeeWhiz catheter device system is designed to help men with urinary incontinence and bladder control." ⁽²⁴⁾

The inclusion of GeeWhiz in LSM’s portfolio not only broadens the company’s product offerings but also positions it as a key player in addressing the needs of individuals with urinary incontinence. This move aligns with the growing demand for innovative healthcare solutions to improve quality of life. ⁽²⁴⁾

Strategic Expansion for a Healthier Future ⁽²⁴⁾

Avalon GloboCare Corp. (Nasdaq: ALBT)’s strategic acquisitions of Merlin Medical Supply and Leading Edge Innovations, LLC, demonstrate the company’s commitment to advancing its position in the healthcare sector. These acquisitions not only open doors to expanded healthcare services but also enhance profit margins by integrating them into LSM’s existing operations.
As the healthcare industry continues to evolve, Avalon’s investments in these accretive businesses underscore its dedication to improving healthcare access, quality, and affordability. With a growing aging population and increasing healthcare demands, Avalon GloboCare Corp. (Nasdaq: ALBT) is poised to play a pivotal role in shaping the future of healthcare delivery.

Avalon GloboCare Corp. (NASDAQ: ALBT) Inks Deal for
Breakthrough AI-Driven Breathalyzer ⁽¹³⁾

Image Source (14)

Avalon GloboCare Corp. (NASDAQ: ALBT) announced a transformative agreement with Qi Diagnostics Limited (Qi Diagnostics). This agreement grants Avalon exclusive distribution rights to market Qi Diagnostics’ groundbreaking KetoAir breathalyzer device and associated accessories, including future models. The distribution will cover North America, South America, the U.K., and the European Union. KetoAir functions as a companion diagnostic and monitoring device for ketogenic dietary management and will initially focus on the diabetes reversal and weight management markets. ⁽¹³⁾

Image Source (15)

Qi Diagnostics is a renowned medical device company specializing in the development and manufacturing of proprietary Volatile Organic Compound (VOC) nanosensor-based in vitro diagnostic and screening devices. Their latest innovation, KetoAir, combines a breathalyzer with artificial intelligence (AI)-powered nutritionist consultation, providing invaluable support for ketogenic health management. Notably, KetoAir holds registration with the United States Food and Drug Administration, showcasing its compliance with regulatory standards.

Image Source (16)

In addition to the distribution agreement, Avalon GloboCare Corp. (NASDAQ: ALBT) and Qi Diagnostics have plans for a collaborative effort to co-develop a breathalyzer device aimed at screening and early detection of lung cancer. The companies will share joint ownership of any intellectual property resulting from this co-development.
Expressing his enthusiasm about the partnership, Dr. David Jin, President and CEO of Avalon GloboCare, stated, “We are very excited to partner with Qi Diagnostics to exclusively distribute KetoAir in key markets. Our initial focus will be on diabetes reversal and obesity management. Scientific evidence has increasingly demonstrated that nutritional ketosis is an effective and sustainable approach for reversing diabetes and managing weight. A properly implemented ketogenic diet has been clinically proven to lower blood sugar, enhance insulin sensitivity, and reduce inflammation.” ⁽¹³⁾
Dr. Jin further emphasized the significance of KetoAir, stating, “KetoAir is the first breathalyzer on the market that combines an AI-powered nutritionist with a nanosensor-based breathalyzer for ketogenic health management. It detects and quantifies acetone levels in the breath, allowing users to monitor their ketosis state while receiving 24/7 nutritional advice. We are eager to bring KetoAir to the market and assist individuals with diabetes and weight management needs.” ⁽¹³⁾
Although the parties intend to finalize a definitive agreement regarding the terms and pricing, there is no guarantee that such an agreement will be reached or deemed acceptable to Avalon GloboCare Corp. (NASDAQ: ALBT). Nonetheless, the collaboration between Avalon GloboCare and Qi Diagnostics holds great promise for advancing the field of ketogenic health management and potentially revolutionizing the way diabetes and weight management are approached. ⁽¹³⁾

Avalon GloboCare Corp. (Nasdaq: ALBT)'s KetoAir™ App Hits Apple App Store… ⁽²⁸⁾

Image Source (29)

In a significant development, Avalon GloboCare Corp. (Nasdaq: ALBT) has unveiled the KetoAir™ mobile application. The application, designed to revolutionize ketogenic dietary management, has been officially launched on the Apple App Store, making it accessible to millions of Apple device users. Additionally, the KetoAir™ mobile application is also available for download on the Google Play Store, ensuring widespread availability. ⁽²⁸⁾
This announcement follows Avalon GloboCare Corp. (Nasdaq: ALBT)’s strategic partnership with Qi Diagnostics, which granted them exclusive distribution rights for KetoAir™ in North America, South America, the U.K., and the EU. The KetoAir™ application combines the capabilities of a companion diagnostic and monitoring device with the expertise of an artificial intelligence (AI) nutritionist consultation. It has been registered with the United States FDA under registration number 3026284320.

A Revolutionary Approach to Ketogenic Health Management ⁽²⁸⁾

KetoAir™ represents a groundbreaking advancement in ketogenic health management. It stands out as the first breathalyzer on the market to integrate an AI nutritionist with a nanosensor-based breathalyzer. This innovative combination empowers individuals seeking to optimize their ketosis state and enhance their body fat burning rate.

Dr. David Jin, President and Chief Executive Officer of Avalon GloboCare Corp., expressed his excitement about the launch, stating, "We are excited to launch the KetoAir app on the Apple App Store. KetoAir™ is the first breathalyzer on the market that uses an AI nutritionist bundled with a nanosensor-based breathalyzer for ketogenic health management. Apple owners can now easily download the app from the Apple App Store, pair your KetoAir™ Breathalyzer device via Bluetooth, and log in to track your ketosis record." ⁽²⁸⁾

The Benefits of KetoAir™ for Health-Conscious Individuals ⁽²⁸⁾

The KetoAir™ breathalyzer device is a compact, pocket-sized tool that delivers accurate and instant results with a single breath. This empowers users to monitor the impact of different foods and activities on their ketone levels in real-time. The AI nutritionist integrated into the app serves as a valuable companion consultant. It analyzes dietary plans and offers personalized nutritional and exercise recommendations to help users achieve their ultimate health goals.

In essence, KetoAir™ offers several key benefits: ⁽²⁸⁾

Real-Time Ketone Monitoring: Users can track their ketosis state in real-time, enabling them to make informed decisions about their diet and lifestyle choices.

Instant Feedback: The breathalyzer provides immediate results, enhancing convenience and usability.

Personalized Guidance: The AI nutritionist tailors recommendations based on individual health goals and preferences, making the ketogenic journey more effective and enjoyable.

Optimized Health and Wellness: For health and wellness-conscious individuals, KetoAir™ offers a comprehensive tool to optimize their ketosis state and achieve their body fat burning goals.

The Future of Ketogenic Health Management ⁽²⁸⁾

As the health and wellness industry continues to expand, innovative solutions like KetoAir™ are poised to play a pivotal role in helping individuals lead healthier lives. Avalon GloboCare Corp.’s commitment to pushing the boundaries of precision diagnostics and laboratory services is evident in this groundbreaking mobile application.
The availability of KetoAir™ on both the Apple App Store and Google Play ensures widespread access, allowing a broader audience to benefit from this cutting-edge technology. With its user-friendly interface, immediate results, and personalized guidance, KetoAir™ represents a significant leap forward in the world of ketogenic health management.
Avalon GloboCare Corp. (Nasdaq: ALBT)’s launch of the KetoAir™ mobile application marks a transformative milestone in the pursuit of optimal health and wellness. With the power of AI and nanosensor technology at their fingertips, individuals can now embark on their ketogenic journey with greater confidence and precision than ever before. ⁽²⁸⁾

3 Reasons:

Innovative Health Management Tool: Avalon GloboCare Corp. (Nasdaq: ALBT) has introduced the groundbreaking KetoAir™ mobile application, combining cutting-edge technology with artificial intelligence to transform the way individuals manage their ketogenic health. This innovative tool provides real-time ketone monitoring, instant feedback, and personalized guidance for health-conscious individuals.

Exclusive Distribution Partnership: ALBT's strategic partnership with Qi Diagnostics has granted them exclusive distribution rights for KetoAir™ in key regions, including North America, South America, the U.K., and the EU. This partnership underscores the potential for widespread adoption and success of the KetoAir™ app in the global health and wellness market.

Revolutionizing Ketogenic Health: KetoAir™ represents a revolutionary approach to ketogenic health management, offering a pocket-sized breathalyzer and AI nutritionist consultation in one app. With the ability to track and optimize ketosis and body fat burning, it's a tool that aligns perfectly with the growing demand for personalized health and wellness solutions in today's world.

Avalon GloboCare Corp. (NASDAQ: ALBT) Secures 16 Patents for Revolutionary Medical Technologies ⁽¹⁷⁾

Image Source (18)

Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the issuance of a key U.S. patent by the United States Patent and Trademark Office (USPTO). The patent, numbered 11,555,060 and titled “QTY Fc Fusion Water Soluble Receptor Proteins,” was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT). This significant achievement expands Avalon’s intellectual property portfolio, showcasing its commitment to advancing medical technologies. ⁽¹⁷⁾

The granted patent encompasses the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. At the core of this breakthrough is the “QTY Code,” a revolutionary technology developed in collaboration with MIT. This innovative platform has the remarkable ability to transform water-insoluble transmembrane receptor proteins into water-soluble proteins, significantly enhancing the solubility of designer peptides and proteins. As a result, the repertoire of selected therapeutic targets against cancers and other diseases is expanded, opening new avenues for medical advancements.

Dr. David Jin, President and Chief Executive Officer of Avalon GloboCare Corp. (NASDAQ: ALBT), expressed his satisfaction with the patent issuance, highlighting the company’s ongoing commitment to intellectual property development. With a total of 16 jointly filed patent applications, Avalon has established fruitful collaborations with esteemed partners, including top-tier universities, renowned research centers, and leading developers in the field. This strong portfolio reinforces Avalon’s position as an innovative contributor to medical advancements.

The QTY code protein design platform, developed in conjunction with Professor Shuguang Zhang’s laboratory at MIT, offers a transformative solution for working with water-insoluble proteins found within cellular membranes. By rendering these proteins water-soluble, the QTY technology enables their utilization in numerous clinical applications. Notably, soluble, antibody-like cytokine/chemokine decoy receptors derived through the QTY protein design hold great potential in various areas, including mitigating the “cytokine storm” associated with certain conditions and broadening the range of therapeutic targets addressable by advanced therapies. ⁽¹⁷⁾

Image Source (19)

Dr. Jin concluded by emphasizing Avalon GloboCare Corp. (NASDAQ: ALBT)’s commitment to innovation and collaboration. In addition to the recently granted patent, the company has also made notable strides in other areas. For instance, Avalon GloboCare Corp. (NASDAQ: ALBT) has plans for a collaborative effort with Qi Diagnostics to co-develop a breathalyzer device aimed at screening and early detection of lung cancer. This collaboration will result in joint ownership of any intellectual property arising from the co-development, further highlighting Avalon’s dedication to advancing medical technologies and improving patient outcomes. ⁽⁸⁾

“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,”

Dr. Jin.⁽³⁵⁾

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Revolutionizes Tuberculosis Diagnosis with Innovative Testing Method… ⁽²⁶⁾

Image Source (30)

In a major stride towards improving healthcare diagnostics, Avalon GloboCare Corp. (Nasdaq: ALBT) is making waves with a groundbreaking tuberculosis (TB) testing method. The company’s subsidiary, Laboratory Services MSO, LLC (“LSM”), has introduced a proprietary polymerase chain reaction (PCR) test that promises to redefine TB diagnosis by providing speed, accuracy, and convenience.

A Game-Changer in Tuberculosis (TB) Diagnosis ⁽²⁶⁾

TB, an airborne infectious disease caused by Mycobacterium tuberculosis (Mtb), is a global health concern, responsible for approximately 1.4 million deaths annually. Traditional diagnostic methods for TB, including the century-old tuberculin skin test, have posed challenges in terms of accuracy, time consumption, and patient convenience.
LSM’s new PCR-based TB test is poised to revolutionize TB diagnosis. Unlike the old skin test that requires multiple clinic visits and chest X-rays for confirmation, LSM’s test provides rapid results within 24 hours with just one clinic visit. This groundbreaking method eliminates the need for needle sticks and utilizes a patient’s sputum sample for detection, making the process far simpler and more patient-friendly.

A Crucial Advancement in TB Control ⁽²⁶⁾

The ability to accurately and swiftly identify Mtb is crucial in controlling the spread of TB and ensuring prompt treatment for affected individuals. TB infection often begins without symptoms in the form of latent TB infection (LTBI), which can persist for extended periods before becoming active and contagious. LSM’s PCR-based test bridges this diagnostic gap, allowing for the early detection of TB, ultimately saving lives and preventing the spread of the disease.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare, emphasized the significance of this innovation, stating, “We believe this is a revolutionary test as it detects a positive result within 24 hours, which is much faster than the old skin test that has to be read after 72 hours, and doesn’t require a blood sample to be collected.”

Advantages of LSM's PCR-Based TB Test ⁽²⁶⁾

Swift Results: LSM's PCR-based test provides results in under 2 hours, significantly reducing waiting times and enabling faster patient management.

Patient-Friendly: With just one clinic visit and no needle stick required, the testing process is convenient and less invasive for patients.

High Accuracy: The proprietary master-mix formulation and PCR amplification method enhance the test's analytical limit of detection, resulting in lower false-positive rates.

Cost-Effective: The test offers higher throughput and lower per-test costs compared to standard diagnostic methods, making it an attractive option for healthcare providers.

Avalon GloboCare Corp. (Nasdaq: ALBT) is set to make this revolutionary TB test accessible to healthcare providers nationwide. As the company continues to push the boundaries of healthcare diagnostics, this advancement showcases its dedication to enhancing healthcare outcomes and delivering innovative solutions that address critical global health challenges. In a world where timely and accurate diagnosis can save lives, the introduction of LSM’s PCR-based TB test represents a significant step towards a healthier future. ⁽²⁶⁾

Avalon GloboCare Corp. (Nasdaq: ALBT) in Summary

Avalon GloboCare Corp. (Nasdaq: ALBT) has emerged as a company worth exploring for those interested in delving into the world of innovative healthcare and life sciences.
With its diverse range of cutting-edge technologies and strategic partnerships, Avalon GloboCare Corp. (Nasdaq: ALBT) is positioning itself as a key player in the rapidly evolving healthcare landscape.

Little-Known Company Harnessing the Power of AI-Breakthroughs Continues with Acquisitions in the $315 Billion Diagnostics Market…^(1)(2)(24)

See why now could be the best time to start your research on Avalon GloboCare Corp. (Nasdaq: ALBT)

NASDAQ: ALBT

Avalon GloboCare Corp. (Nasdaq: ALBT)

7 Reasons Why Avalon GloboCare Corp. (Nasdaq: ALBT) Could See Significant Upside Potential Ahead of 2024...

NASDAQ: ALBT

Active Chart:
Shares of Avalon GloboCare Corp. (Nasdaq: ALBT) have demonstrated the potential for a significant upside potential of over 664% after recently bouncing off their 52-week low of $.68 on 10/03/2023 and eyeing this year’s high of $5.20 set on 1/5/2023. Not that any returns to previous highs are certain for (ALBT) shares, but the potential for 664% upside, after bouncing off their 52-week low, suggests a strong reason to begin your research on this company. ⁽³⁾

Strategic Acquisitions:
In a strategic move aimed at bolstering its presence in the healthcare industry and tapping into the lucrative $315 billion diagnostics market, Avalon GloboCare Corp. (Nasdaq: ALBT) has continued its acquisition spree, building upon its previous acquisition by making significant new additions through its subsidiary, Laboratory Services MSO, LLC. These acquisitions include Merlin Medical Supply, a reputable HME and DME company in Ventura County, California, as well as Leading Edge Innovations, LLC, the owner of the patented FDA-registered GeeWhiz External Condom Catheter. ^(6)(2)(24)

Extremely Low Float:
Stocks with low floats have the potential to present significant swings due to their volatile nature. MarketWatch.com is reporting on 10/16/2023 that Avalon GloboCare Corp. (Nasdaq: ALBT) has fewer than 4.7 million shares available in its public float. ⁽⁴⁾⁽⁵⁾

Artificial Intelligence:
Avalon GloboCare Corp. (Nasdaq: ALBT) has secured exclusive rights to the KetoAir™ which is the first breathalyzer on the market that uses an artificial intelligence (AI) nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management. ⁽⁸⁾

Intellectual Property:
In a significant stride towards pioneering medical innovation, Avalon GloboCare Corp. (Nasdaq: ALBT) has achieved a remarkable milestone. The United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled "QTY Fc Fusion Water Soluble Receptor Proteins." This patent represents a groundbreaking achievement in the realm of molecular biology and has the potential to reshape the landscape of therapeutic targeting. ⁽²⁵⁾

Meeting Growing FDA-Regulated Healthcare Needs:
As the FDA-regulated medical supply market is poised for rapid growth due to an aging population, Avalon GloboCare Corp. (Nasdaq: ALBT)’s acquisitions of Merlin Medical Supply and Leading Edge Innovations are well-timed to meet the rising demand for FDA-compliant healthcare solutions. This positions the company as a key player in addressing the evolving FDA-regulated healthcare landscape. ⁽²⁴⁾

Game-Changing Diagnostics:
The revolutionary PCR-based Tuberculosis test developed by LSM, a subsidiary of Avalon GloboCare Corp. (Nasdaq: ALBT), is transforming TB diagnosis. Differing from conventional methods, it delivers swift results within 24 hours, necessitates just one clinic visit, and eliminates the need for invasive needle sticks. This groundbreaking advancement bridges the gap in early TB detection, ultimately saving lives and controlling the spread of the disease. (26)⁽²⁶⁾

Source List

Source 1: https://finance.yahoo.com/news/avalon-globocare-reports-laboratory-services-130000718.html
Source 2: https://www.precedenceresearch.com/clinical-laboratory-service-market
Source 3: https://www.barchart.com/stocks/quotes/ALBT/price-history/historical
Source 4: https://stockstotrade.com/low-float-stocks/
Source 5: https://www.marketwatch.com/investing/stock/albt?mod=search_symbol
Source 6: https://finance.yahoo.com/news/avalon-globocare-announces-closing-strategic-140000910.html
Source 7: https://www.avalon-globocare.com/investors/sec-filings/all-sec-filings/content/0001213900-23-049645/0001213900-23-049645.pdf
Source 8: https://www.avalon-globocare.com/investors/news-events/press-releases/detail/105/avalon-globocare-signs-agreement-with-qi-diagnostics-to
Source 9: https://www.globenewswire.com/en/news-release/2023/01/17/2590028/0/en/Avalon-GloboCare-Announces-Issuance-of-Key-U-S-Patent-for-Multiple-Novel-QTY-Code-Modified-Cytokine-and-Chemokine-Protein-Receptor-Molecules.html
Source 10: https://schrts.co/BYBJQHGr
Source 11: https://d1io3yog0oux5.cloudfront.net/_cd572f6352352522e1b55add97a68f17/avalonglobocare/db/600/5017/pdf/ALBT+June+2023-Final.pdf
Source 12: https://assets.technologynetworks.com/production/dynamic/images/content/328512/top-10-diagnostics-news-stories-of-2019-328512-960×540.jpg?cb=10499578
Source 13: https://finance.yahoo.com/news/avalon-globocare-signs-agreement-qi-130000275.html
Source 14: https://etimg.etb2bimg.com/photo/96983450.cms
Source 15: https://qidiagnostics.com/wp-content/uploads/2023/04/KetoAir_%E5%B7%A5%E4%BD%9C%E5%8D%80%E5%9F%9F-1.jpg
Source 16: https://medtechintelligence.com/wp-content/uploads/2022/12/FDA-Logo.jpg
Source 17: https://www.avalon-globocare.com/investors/news-events/press-releases/detail/102/avalon-globocare-announces-issuance-of-key-u-s-patent-for
Source 18: https://www.mit.edu/files/images/201807/15656704711_00457bd2c9_b_1.jpg
Source 19: https://qidiagnostics.com/wp-content/uploads/2022/10/INOSE2-e1666587303668.png
Source 20: https://www.investopedia.com/articles/stocks/05/042605.asp
Source 21: https://www.investopedia.com/ask/answers/121214/what-are-best-indicators-identify-overbought-and-oversold-stocks.asp
Source 22: https://finance.yahoo.com/news/avalon-laboratory-services-mso-acquires-130000942.html
Source 23: https://www.alfascientific.com/wp-content/uploads/2017/03/IVD-testing.jpg
Source 24: https://finance.yahoo.com/news/avalon-laboratory-services-mso-acquires-131500621.html
Source 25: https://finance.yahoo.com/news/avalon-globocare-announces-notice-publication-120000352.html
Source 26: https://finance.yahoo.com/news/avalon-laboratory-services-mso-launches-130000037.html
Source 27: https://news.harvard.edu/wp-content/uploads/2023/04/AI-cardiologist-heart-diagnostics_1200x800.jpg
Source 28: https://finance.yahoo.com/news/apple-approves-avalon-globocare-ketoair-130000021.html
Source 29: https://i.dailymail.co.uk/1s/2022/09/20/15/62372507-0-image-a-8_1663684371530.jpg
Source 30: https://laboratoriobioclinic.cr/wp-content/uploads/2023/05/Tuberculosis-Que-es-contagio-y-sintomas.jpeg
Source 31: https://store.urinedevice.com/cdn/shop/products/geewhiz-w-desc-700px_large.jpg?v=1527686988
Source 32: https://schrts.co/TaeEKckU

Legal Disclaimer

This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

COMPENSATION

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 08/01/2022 and ending on 08/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid fifty thousand dollars USD. We own zero shares of (ALBT:US)

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 09/23/2022 and ending on 09/30/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional fifty thousand dollars USD. To date we have been paid one hundred thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 10/03/2022 and ending on 10/07/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid one hundred twenty five thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 10/10/2022 and ending on 10/14/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid one hundred fifty thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 10/17/2022 and ending on 10/21/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid one hundred seventy five thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 10/24/2022 and ending on 10/28/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid two hundred thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 10/31/2022 and ending on 11/03/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional ten thousand dollars USD. To date we have been paid two hundred ten thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/04/2022 and ending on 11/07/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional one hundred thousand dollars USD. To date we have been paid three hundred ten thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 12/09/2022 and ending on 01/04/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional one hundred thousand dollars USD. To date we have been paid five hundred ten thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 01/05/2023 and ending on 01/17/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional one hundred thousand dollars USD. To date we have been paid six hundred ten thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 01/18/2023 and ending on 01/20/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional fifty thousand dollars USD. To date we have been paid six hundred sixty thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 01/23/2023 and ending on 02/03/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional fifty thousand dollars USD. To date we have been paid seven hundred ten thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 02/06/2023 and ending on 02/10/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid seven hundred thirty five thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 02/13/2023 and ending on 02/17/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional fifty thousand dollars USD. To date we have been paid seven hundred eighty five thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 02/21/2023 and ending on 02/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid eight hundred ten thousand dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 02/21/2023 and ending on 02/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional seventeen thousand five hundred dollars USD. To date we have been paid eight hundred twenty seven thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/01/2023 and ending on 03/03/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid eight hundred fifty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/06/2023 and ending on 03/10/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional forty thousand dollars USD. To date we have been paid eight hundred ninety two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/17/2023 and ending on 03/21/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional forty thousand dollars USD. To date we have been paid nine hundred thirty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 11/08/2022 and ending on 12/08/2022 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid one hundred thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid nine hundred fifty seven thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 03/27/2023 and ending on 03/31/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional forty thousand dollars USD. To date we have been paid nine hundred ninety seven thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 04/03/2023 and ending on 04/07/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional forty thousand dollars USD. To date we have been paid one million thirty seven thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 04/10/2023 and ending on 04/14/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid one million sixty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 04/17/2023 and ending on 04/17/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional ten thousand dollars USD. To date we have been paid one million seventy two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 04/25/2023 and ending on 04/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional twenty thousand dollars USD. To date we have been paid one million ninety two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 05/03/2023 and ending on 05/03/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional ten thousand dollars USD. To date we have been paid one million one hundred two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 07/10/2023 and ending on 07/10/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional forty thousand dollars USD. To date we have been paid one million one hundred forty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 07/18/2023 and ending on 07/19/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional one hundred ten thousand dollars USD. To date we have been paid one million two hundred fifty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 07/20/2023 and ending on 08/03/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional one hundred thousand dollars USD. To date we have been paid one million three hundred fifty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 07/31/2023 and ending on 07/31/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional thirty thousand dollars USD. To date we have been paid one million three hundred eighty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

Pursuant to an agreement between TD Media LLC and Exchange Listing LLC, TD Media LLC has been hired for a period beginning on 03/22/2023 and ending on 03/24/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid twenty five thousand dollars USD. Pursuant to an agreement between TD Media LLC and Strategica LLC, TD Media LLC has been hired for a period beginning on 02/27/2023 and ending on 02/28/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid seventeen thousand five hundred dollars USD. Pursuant to an agreement between TD Media LLC and Avalon GloboCare Corp., TD Media LLC has been hired for a period beginning on 09/18/2023 and ending on 09/25/2023 to publicly disseminate information about (ALBT:US) via digital communications. We have been paid an additional fifty thousand dollars USD. To date we have been paid one million four hundred thirty two thousand five hundred dollars USD to disseminate information about (ALBT:US) via digital communications. We own zero shares of (ALBT:US).

(Last updated: 12-08-2023 7:49:05)

Little-Known Company Harnessing the Power of AI-Breakthroughs Continues with Acquisitions in the $315 Billion Diagnostics Market… (1)(2)(24)

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon’s Laboratory Services MSO Announces Expansion into Arizona

Avalon GloboCare Corp. (Nasdaq: ALBT)

7 Reasons Why Avalon GloboCare Corp. (Nasdaq: ALBT) Could See Significant Upside Potential Ahead of 2024...

Active Chart:

Strategic Acquisitions:

Extremely Low Float:

Artificial Intelligence:

Intellectual Property:

Meeting Growing FDA-Regulated Healthcare Needs:

Game-Changing Diagnostics:

Avalon GloboCare Corp. (Nasdaq: ALBT)

Promising Growth Prospects in the Global Clinical Laboratory Service Market (2)

Avalon GloboCare Corp. (Nasdaq: ALBT)

Could Avalon GloboCare Corp. (Nasdaq: ALBT) Have as Much as 664% Potential Upside After Recently Bouncing Off Its 52-Week Low? (3)

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Makes Strategic Move in $315 Billion Diagnostics Market with Acquisition… (1)(2)

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Expands its Reach with Strategic Acquisition of DE Laboratory… (22)

SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Expands its Healthcare Footprint with Strategic Acquisitions… (24)

MMS: A Thriving Medical Supply Company (24)

GeeWhiz: A Game-Changing Male Catheter Device (24)

Strategic Expansion for a Healthier Future (24)

Avalon GloboCare Corp. (NASDAQ: ALBT) Inks Deal for Breakthrough AI-Driven Breathalyzer (13)

Avalon GloboCare Corp. (Nasdaq: ALBT)'s KetoAir™ App Hits Apple App Store… (28)

A Revolutionary Approach to Ketogenic Health Management (28)

The Benefits of KetoAir™ for Health-Conscious Individuals (28)

In essence, KetoAir™ offers several key benefits: (28)

The Future of Ketogenic Health Management (28)

3 Reasons:

Avalon GloboCare Corp. (NASDAQ: ALBT) Secures 16 Patents for Revolutionary Medical Technologies (17)

Avalon GloboCare Corp. (Nasdaq: ALBT)

Avalon GloboCare Corp. (Nasdaq: ALBT) Revolutionizes Tuberculosis Diagnosis with Innovative Testing Method… (26)

A Game-Changer in Tuberculosis (TB) Diagnosis (26)

A Crucial Advancement in TB Control (26)

Advantages of LSM's PCR-Based TB Test (26)

Avalon GloboCare Corp. (Nasdaq: ALBT) in Summary